|
|
Ended the quarter with $42.9 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025 Positive 11month topline efficacy data presented at the 46th Annual Charing Cross Symposium Company on track to file PMA Application seeking VenoValve® FDA approval in Q4 2024IRVINE, CA / ACCESSWI... Lire le communiqué |
|
| |
|
| |
|
|
Overall 8.46 Average Revised Venous Clinical Severity Score rVCSS Improvement Per Patient for Patients Showing Clinical Meaningful Benefit rVCSS Improvement ≥ 3 Points including:9.29 Points for Patients at the TwoYear Milestone8.08 Points for Patients at the OneYear Milestone8.71 Points for Patients at the SixMonth Milestone... Lire le communiqué |
|
| |
|
| |
|
|
IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation NASDAQ:NVNO "enVVeno" or the "Company", a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from the VenoValve U.S. pivotal trial will be presented at the 2024 Charing Cross International Symposium being held April 23rd 25th in... Lire le communiqué |
|
| |
|
| |
|
|
Appointment bolsters Companys transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation NASDAQ:NVNO "enVVeno" or the "Company", a company setting new standards of... Lire le communiqué |
|
| |
|
| |
|
|
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation NASDAQ:NVNO "enVVeno" or the "Company", a company setting new standards of care for the treatment of venous disease, today announced that it will present at the Virtual Investor L... Lire le communiqué |
|
| |
|
| |
|
|
97% of VenoValve Study Patients Showing Clinical Improvement at Six Months as Measured by the Revised Venous Clinical Severity Score rVCSS74% of the Study Patients Showing Clinical Meaningful Benefit from the VenoValve at Six Months Improvement in rVCSS of 3 or More PointsAverage rVCSS Improvement Per Patient is 8 Points, More Than Two and a Half Times the Amount Needed to Show the VenoValves... Lire le communiqué |
|
| |
|
| |
|
|
$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve® U.S. pivotal trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024Continued progress toward launch of GLP study for enVVe® transcatheterbased replacement venous... Lire le communiqué |
|
| |
|
| |
